Delaware Court Raises Bar for Use of “Poison Put” Provisions

David A. Katz is a partner at Wachtell, Lipton, Rosen & Katz specializing in the areas of mergers and acquisitions and complex securities transactions. This post is based on a Wachtell Lipton memorandum by Mr. Katz, Igor Kirman and Ryan A. McLeod. This post is part of the Delaware law series, which is cosponsored by the Forum and Corporation Service Company; links to other posts in the series are available here. Further reading about Kallick v. SandRidge Energy, Inc. is available here.

In a recent case that arose in the context of a consent solicitation seeking a change of control of a public company, the Delaware Court of Chancery found the target board in breach of its fiduciary duties for not approving a dissident slate for the purposes of preventing a change-of-control-triggered put right in the company’s debt agreements. Kallick v. SandRidge Energy, Inc., C.A. No. 8182-CS (Del. Ch. Mar. 8, 2013). Chancellor Strine’s ruling extends prior Delaware law on the topic and provides cautionary guidance about the future effectiveness of such clauses, which are common features of debt documents and other commercial arrangements.

The case arose out of a hedge fund’s efforts to destagger and replace a majority of the board of directors of SandRidge Energy via a consent solicitation. In opposing the consent solicitation, the company initially warned shareholders that a change in the majority of the board that was not approved by the company’s directors would obligate the company to offer to repurchase $4.3 billion of debt at 101% of par pursuant to certain provisions in its debt instruments—provisions sometimes called “poison puts” or “proxy puts.” The company subsequently changed its public posture and noted that the put was “unlikely” to be harmful, because the debt was then trading above par, making it doubtful that the put would be exercised. However, the board failed to decide whether to “approve” the dissident nominees for purposes of the debt documents, thus leaving a cloud of uncertainty regarding the put and drawing a legal challenge from a shareholder.

Noting Delaware’s sensitivity towards the stockholder franchise, Chancellor Strine applied Unocal’s intermediate standard of review both to the board’s decision to agree to the “poison put” provisions in the first place and to its subsequent conduct with respect to such clauses. Citing former Vice Chancellor Lamb’s 2009 decision in Amylin, the Court explained that a board has the power and, so long as it is complying with the contractual implied covenant of good faith and fair dealing, also the right to approve dissident nominees for purposes of avoiding the triggering of a poison put—even while the board is conducting a public campaign against those nominees. Although the Court briefly acknowledged that poison put provisions are often requested by the lenders, and may benefit companies through better debt terms, it nonetheless narrowly cabined the board’s discretion in this context, requiring the board to approve the dissident nominees unless passing control to them would constitute a breach of the duty of loyalty. According to Chancellor Strine, it is not enough for a board to believe that it is better qualified, or has better plans, than the dissident slate. Instead, a board may only decline to approve dissident nominees where the board can “identify that there is a specific and substantial risk to the corporation or its creditors posed by the rival slate” (such as by showing the nominees “lack the integrity, character, and basic competence to serve in office”) or where the dissident slate has announced plans that might affect the company’s ability to “repay its creditors.” The Court found that the directors here failed to identify such a threat, and enjoined them from opposing the consent solicitation until they approved the dissident nominees (shortly after the Court’s ruling, the board approved the nominees and the two sides subsequently settled the contest). The Court also observed that boards may have greater flexibility in applying change-of-control clauses in other contexts like employment agreements, where the employee beneficiaries of those agreements may have a more extensive concern for the identity of their bosses.

Chancellor Strine’s decision emphasizes the heightened level of scrutiny Delaware courts will apply in the context of shareholder voting rights, even when, as here, there was not a significant showing of actual coercive harm. It also raises serious questions about how future change-of-control provisions will be drafted and negotiated, since contractual considerations will continue to play a role in Delaware’s analysis of these provisions and companies must also consider how to properly disclose the limitations on such provisions. The decision is a further reminder that boards should engage in a careful, well-documented process whenever they enter into or apply contractual provisions that could affect shareholder voting.

Post a comment or leave a trackback: Trackback URL.

Post a Comment

Your email is never published nor shared. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

  • Subscribe

  • Cosponsored By:

  • Supported By:

  • Programs Faculty & Senior Fellows

    Lucian Bebchuk
    Alon Brav
    Robert Charles Clark
    John Coates
    Alma Cohen
    Stephen M. Davis
    Allen Ferrell
    Jesse Fried
    Oliver Hart
    Ben W. Heineman, Jr.
    Scott Hirst
    Howell Jackson
    Robert J. Jackson, Jr.
    Wei Jiang
    Reinier Kraakman
    Robert Pozen
    Mark Ramseyer
    Mark Roe
    Robert Sitkoff
    Holger Spamann
    Guhan Subramanian

  • Program on Corporate Governance Advisory Board

    William Ackman
    Peter Atkins
    Joseph Bachelder
    John Bader
    Allison Bennington
    Richard Brand
    Daniel Burch
    Richard Climan
    Jesse Cohn
    Isaac Corré
    Scott Davis
    John Finley
    David Fox
    Stephen Fraidin
    Byron Georgiou
    Carl Icahn
    Jack B. Jacobs
    Paula Loop
    David Millstone
    Theodore Mirvis
    James Morphy
    Toby Myerson
    Morton Pierce
    Barry Rosenstein
    Paul Rowe
    Rodman Ward